Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control studyResearch in context

Autor: Avi Kenny, Janine van Duijn, One Dintwe, Jack Heptinstall, Randy Burnham, Sheetal Sawant, Lu Zhang, Dieter Mielke, Sharon Khuzwayo, Faatima Laher Omar, Sherry Stanfield-Oakley, Taylor Keyes, Brooke Dunn, Derrick Goodman, Youyi Fong, David Benkeser, Rodger Zou, John Hural, Ollivier Hyrien, Michal Juraska, Alex Luedtke, Lars van der Laan, Elena E. Giorgi, Craig Magaret, Lindsay N. Carpp, Laura Pattacini, Tom van de Kerkhof, Bette Korber, Wouter Willems, Leigh H. Fisher, Hanneke Schuitemaker, Edith Swann, James G. Kublin, Maria G. Pau, Susan Buchbinder, Frank Tomaka, Steven Nijs, Ludo Lavreys, Huub C. Gelderblom, Lawrence Corey, Kathryn Mngadi, Glenda E. Gray, Erica Borducchi, Jenny Hendriks, Kelly E. Seaton, Susan Zolla-Pazner, Dan H. Barouch, Guido Ferrari, Stephen C. De Rosa, M Juliana McElrath, Erica Andersen-Nissen, Daniel J. Stieh, Georgia D. Tomaras, Peter B. Gilbert, Jon Allagappen, Jessica Andriesen, Alison Ayres, Saman Baral, Linda-Gail Bekker, Asiphe Besethi, Caroline Borremans, Esmee Braams, Caroline Brackett, William Brumskine, Roma Chilengi, Rachel Choi, Thozama Dubula, Jaiden Seongmi Dumas, Radhika Etikala, Zelda Euler, Sarah Everett, Nigel Garrett, Huub Gelderblom, Katherine Gill, Kevin Gillespie, Dimitri Goedhart, Erik Goosmann, Shannon Grant, Ellie Hands, Barton Haynes, Bronwill Herringer, Zaheer Hoosain, Mina Hosseinipour, Portia Hunidzarira, Julia Hutter, Mubiana Inambao, Craig Innes, William Kilembe, Philippus Kotze, Sheena Kotze, Fatima Laher, Imre Laszlo, Erica Lazarus, Hua-Xin Liao, Yong Lin, Helen Lu, Judith Lucas, Mookho Malahleha, Tara McNair, Peter Meerts, Zinhle Mgaga, Mahlodi Montlha, Boitumelo Mosito, Andrew Moultrie, Sarah Mudrak, Valérie Oriol-Mathieu, Marcella Sarzotti-Kelsoe, Matson Tso Mathebula, Mitch Matoga, Rachael McClennen, Pamela Mda, Vimla Naicker, Logashvari Naidoo, Cindy-Ann Okkers, Saleha Omarjee, Hella Pasmans, Tricia Philip, Abraham Pinter, Annah Pitsi, Ornelia Ramos, April Randhawa, Sanne Roels, Shamiska Rohith, Lucy Rutten, Jerald Sadoff, Gabriela Salinas, Yvonne Salzgeber, Lorenz Scheppler, Katharine Schwedhelm, Nicolette Schuller, Angelina Sharak, Carrie Sopher, Terence Tafatatha, Simbarashe G. Takuva, Chan Tang, An Vandebosch, Edna Viegas, Valentin Voillet, Frank Wegmann, Mo Weijtens, Stephany Wilcox, Anthony Williams, Chenchen Yu, Pei-Chun Yu, Olive Yuan, Xuehan Zhang

Publikováno v: EBioMedicine, Vol 108, Iss , Pp 105320- (2024)

Summary: Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based vaccine (Ad26.Mos4.HIV) at Months 0

Externí odkaz: https://doaj.org/article/f41b2bdf77344ddab5c165f46025f8a4

Addressing missed visits to improve retention of young South African women in clinical trials

Autor: Khatija Ahmed, Mookho Malahleha, Thulisile E. Mbatsane, Dineo Thindisa, Veronique C. Bailey, Ishen Seocharan, Athmanundh Dilraj

Publikováno v: South African Journal of Science, Vol 119, Iss 7/8 (2023)

In clinical trials, a vital protocol requirement for participants is adherence to scheduled visits. A substantial number of missed visits and the resultant missing data could affect generalisability of the findings and undermine the scientific conclu

Externí odkaz: https://doaj.org/article/9fbf07c3eca34687a333088094e649d9

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.

Autor: Fatima Laher, Zoe Moodie, Kristen W Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B Gilbert, Sanjay Phogat, Carlos A DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N Mkhize, Michael N Pensiero, Vijay L Mehra, James G Kublin, Lawrence Corey, David C Montefiori, Glenda E Gray, M Juliana McElrath, Georgia D Tomaras

Publikováno v: PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)

BackgroundHVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses.Methods and findingsA phase 1-2 randomized double-blind placebo-co

Externí odkaz: https://doaj.org/article/a8f5e1efa20e4dca897e71b9fcfdaef2

Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

Autor: Zoe Moodie, One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes, Jack Heptinstall, Faatima Laher Omar, Kristen Cohen, Stephen C De Rosa, Lu Zhang, Nicole L Yates, Marcella Sarzotti-Kelsoe, Kelly E Seaton, Fatima Laher, Linda Gail Bekker, Mookho Malahleha, Craig Innes, Sheetal Kassim, Nivashnee Naicker, Vaneshree Govender, Modulakgotla Sebe, Nishanta Singh, Philip Kotze, Erica Lazarus, Maphoshane Nchabeleng, Amy M Ward, William Brumskine, Thozama Dubula, April K Randhawa, Nicole Grunenberg, John Hural, Jia Jin Kee, David Benkeser, Yutong Jin, Lindsay N Carpp, Mary Allen, Patricia D’Souza, James Tartaglia, Carlos A DiazGranados, Marguerite Koutsoukos, Peter B Gilbert, James G Kublin, Lawrence Corey, Erica Andersen-Nissen, Glenda E Gray, Georgia D Tomaras, M Juliana McElrath

Publikováno v: J Infect Dis

Background The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbc0ea13558e3c67abc2064a240ddabb
https://doi.org/10.1093/infdis/jiac260

Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern

Autor: Anthonet L. Koen, Alane Izu, Vicky Baillie, Gaurav Kwatra, Clare L. Cutland, Lee Fairlie, Sherman D. Padayachee, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Khatija Ahmed, Sutika Bhikha, Jinal N. Bhiman, Jeanine du Plessis, Aliasgar Esmail, Elizea Horne, Shi-Hsia Hwa, Aylin Oommen-Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Gabriella Benade, Shakeel McKenzie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Tonya L. Villafana, Sarah Gilbert, Andrew J. Pollard, Shabir A. Madhi

In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-type and 77.1% against the Delta variant ≥9 months after vaccination. VE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::90f5a6d20644392d1f0fb82c06d8b6c8
https://doi.org/10.1101/2022.07.18.22277743